AZD2811 not checked

AstraZeneca · AZD1152 hQPA

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
2 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“IV infusions through maintenance phase until PD or other discontinuation criteria.”In the company’s words, NCT04745689 on ClinicalTrials.gov
Tested for
Small-Cell Lung Cancer
Main trialPhase 2
“A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients with Extensive Stage Small-Cell Lung Cancer.”In the company’s words, NCT04745689 on ClinicalTrials.gov
Other names
AZD1152 hQPA

Other drugs for Small-Cell Lung Cancer

All 118 drugs for Small-Cell Lung Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 18 Jun 2022 Study of AZD2811 + Durvalumab in ES-SCLC
Phase 1Terminated 25 Mar 2021 Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow AZD2811

Following is part of Solo: you see every change to AZD2811 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in